[시장보고서]아시아태평양 및 중동의 NGS 시장 : 오퍼링별, 워크플로우별, 플랫폼별, Throughput별, 기술 유형별, 용도별, 최종사용자별, 국가별

아시아태평양 및 중동의 NGS 시장 : 오퍼링별, 워크플로우별, 플랫폼별, Throughput별, 기술 유형별, 용도별, 최종사용자별, 국가별 - 분석과 예측(2025-2035년)

Asia-Pacific and Middle East NGS Market: Focus on Offering, Platform, Throughput, Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035

상품코드 : 1679111

리서치사 : BIS Research

발행일 : 2025년 03월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

아시아태평양 및 중동의 차세대 염기서열 분석(NGS) 시장은 차세대 염기서열 분석 기술의 급속한 발전, 유전성 질환 및 암 유병률 증가, 정밀의료 분야에서의 차세대 염기서열 분석 적용 확대 등을 배경으로 크게 성장하고 있습니다.

차세대 시퀀싱 플랫폼의 끊임없는 기술 혁신으로 효율성, 정확성, 비용 효율성이 향상되면서 차세대 시퀀싱은 임상 진단과 연구 목적 모두에서 더 쉽게 사용할 수 있게 되었습니다. 맞춤형 의료, 특히 종양학, 생식 의학 및 감염성 질환 진단 분야에서 차세대 시퀀싱에 대한 수요가 증가함에 따라 시장 확대가 더욱 가속화되고 있습니다. 또한 정부의 강력한 구상, R&D 투자 증가, 생명공학 기업 및 의료 서비스 프로바이더와의 전략적 제휴가 이 지역의 차세대 염기서열 분석 시장의 성장을 가속하고 있습니다. 중국, 인도, 사우디아라비아 등의 국가들은 질병의 조기 발견과 정밀의료를 촉진하기 위한 대규모 유전체 프로젝트를 주도하고 있으며, 이는 아시아태평양 및 중동의 NGS 시장 전망을 더욱 강화시키고 있습니다.

차세대 시퀀싱 시장은 큰 성장 잠재력을 가지고 있지만, 몇 가지 과제도 남아있습니다. 차세대 염기서열 분석 플랫폼, 소모품, 데이터 분석 툴와 관련된 높은 비용은 특히 저소득 지역에서 여전히 큰 장벽으로 작용하고 있습니다. 바이오인포매틱스 및 유전체 데이터 분석에 숙련된 전문가의 부족은 차세대 시퀀싱 기술의 보급을 더욱 가로막고 있습니다. 또한 데이터 프라이버시, 보안 및 규제 준수에 대한 우려는 여러 국가에서 차세대 염기서열분석을 시행하는 데 있으며, 복잡성을 야기하고 있습니다. 또한 헬스케어 규제와 유전체 데이터 활용에 대한 윤리적 우려로 인해 특정 지역에서는 차세대 염기서열 분석의 도입이 더욱 어려워지는 등 시장 성장 억제요인으로 작용하고 있습니다. 이러한 요인들은 아시아태평양 및 중동의 NGS 시장에 도전이 되고 있습니다.

그럼에도 불구하고 아시아태평양 및 중동의 차세대 염기서열 분석 시장에는 큰 성장 기회가 있습니다. 헬스케어 인프라가 빠르게 개선되고 있는 신흥 국가에서는 차세대 염기서열 분석 연구 및 임상 응용에 대한 투자가 증가하고 있습니다. 인공지능(AI)과 클라우드 기반 바이오인포매틱스의 통합은 유전체 데이터 분석에 혁명을 일으켜 차세대 시퀀싱을 보다 효율적이고 쉽게 이용할 수 있도록 하고 있습니다. 또한 비침습적 산전검사(NIPT)와 감염성 질환 연구에 차세대 염기서열 분석의 활용이 확대되면서 시장 진출기업에게 새로운 성장의 길을 제공합니다. 정부 및 민간 기업이 유전체 연구, 정밀의료 및 임상 적용에 대한 투자를 지속함에 따라 아시아태평양 및 중동의 차세대 염기서열 분석 시장은 향후 수년간 크게 성장할 것으로 예상됩니다.

아시아태평양 및 중동의 NGS 시장에 대해 조사했으며, 시장의 개요와 오퍼링별, 워크플로우별, 플랫폼별, throughput별, 기술 유형별, 용도별, 최종사용자별, 국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

경쟁 벤치마킹
경쟁 구도
- 각사의 주요 전략과 개발
- 시장 점유율 분석,2024-2035
- 아시아태평양 및 중동의 NGS 시장의 성장 점유율 분석(최종사용자별)
- 아시아태평양 및 중동의 NGS 시장의 성장 점유율 분석(Throughput별)
기업 개요
- BGI Group
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
신규 기업(아시아태평양 및 중동)

KSA

영문 목차

영문목차

Asia-Pacific and Middle East NGS Market Industry Overview

The Asia-Pacific and Middle East Next-Generation Sequencing (NGS) market is experiencing significant growth, driven by rapid advancements in next-generation sequencing technologies, the rising prevalence of genetic disorders and cancer, and the expanding application of next-generation sequencing in precision medicine. Continuous innovations in next-generation sequencing platforms have enhanced efficiency, accuracy, and cost-effectiveness, making next-generation sequencing more accessible for both clinical diagnostics and research purposes. The increasing demand for next-generation sequencing in personalized medicine, particularly in oncology, reproductive health, and infectious disease diagnostics, is further fueling market expansion. Additionally, strong government initiatives, increased R&D investments, and strategic collaborations between biotech firms and healthcare providers are propelling the growth of next-generation sequencing in the region. Countries such as China, India, and Saudi Arabia are leading large-scale genomic projects to advance early disease detection and precision healthcare, further strengthening the Asia-Pacific and Middle East NGS market landscape.

Despite the strong growth potential of the next-generation sequencing market, several challenges persist. The high cost associated with next-generation sequencing platforms, consumables, and data analysis tools remains a major barrier, particularly in low-income regions. The shortage of skilled professionals proficient in bioinformatics and genomic data interpretation further hinders the widespread adoption of next-generation sequencing technologies. Moreover, concerns related to data privacy, security, and regulatory compliance create complexities in the implementation of next-generation sequencing across different countries. Additionally, variations in healthcare regulations and ethical concerns surrounding genomic data usage add to the market's constraints, making the adoption of next-generation sequencing more challenging in certain regions. This factor is posing a challenge for the Asia-Pacific and Middle East NGS market.

Nevertheless, the next-generation sequencing market in the Asia-Pacific and Middle East regions presents significant opportunities for expansion. Emerging economies with rapidly improving healthcare infrastructure are increasingly investing in next-generation sequencing research and clinical applications. The integration of artificial intelligence (AI) and cloud-based bioinformatics is revolutionizing genomic data analysis, making next-generation sequencing more efficient and accessible. Furthermore, the growing use of next-generation sequencing in non-invasive prenatal testing (NIPT) and infectious disease research offers new growth avenues for market players. As governments and private sector companies continue investing in genomic research, precision medicine, and clinical applications, the next-generation sequencing market in Asia-Pacific and the Middle East is poised for substantial expansion in the coming years.

Impact of COVID-19

Next-generation sequencing (NGS)-based products play a vital role in disease research and diagnostics, particularly in cancer detection and treatment, where next-generation sequencing enables personalized and targeted therapies for patients. The next-generation sequencing market is primarily driven by manufacturers of next-generation sequencing instruments, kits, assays, and service providers offering gene panels and oncology-focused testing services using next-generation sequencing technology. However, the COVID-19 pandemic negatively impacted revenue growth in the next-generation sequencing market due to disruptions in supply chains and healthcare operations, affecting the availability of next-generation sequencing products and services.

Despite these challenges, the pandemic underscored the critical role of next-generation sequencing in public health management, particularly in sequencing the SARS-CoV-2 virus, tracking its mutations, and monitoring population health. For example, in October 2022, Kyrgyzstan initiated efforts to enhance its next-generation sequencing capabilities for SARS-CoV-2 surveillance. Industry leaders in next-generation sequencing anticipate a shift toward local manufacturing to reduce dependence on imports, as the pandemic exposed weaknesses in global supply chains. Consequently, several countries in the Asia-Pacific and Middle East regions are prioritizing domestic production of essential medical supplies and next-generation sequencing tools to ensure a more stable and resilient healthcare infrastructure, propelling the the overall Asia-Pacific and Middle East NGS market.

The growth of the next-generation sequencing market is fueled by the increasing adoption of next-generation sequencing in diverse research and diagnostic applications, the rising prevalence of non-communicable diseases, and continuous advancements in next-generation sequencing platforms that enhance efficiency, speed, and accuracy. As the demand for next-generation sequencing continues to rise, innovations in next-generation sequencing technology will further drive market expansion, positioning next-generation sequencing as a fundamental tool in modern genomics and precision medicine.

Market Segmentation:

Segmentation 1: by Offerings

Consumables
Equipment
Services

The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment.

Segmentation 2: by Platform

Illumina, Inc.
Thermo Fisher Scientific Inc.
Pacific BioSciences of California, Inc.
Oxford Nanopore Technologies plc.
Other Companies

The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc.

Segmentation 3: by Throughput

High-Throughput
Medium-Throughput
Low-Throughput

The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment.

Segmentation 4: by Technology Type

Sequencing by Synthesis
In Torrent Semiconductor Sequencing
Single Molecule Real-Time Sequencing
Nanopore Sequencing Technology
Other Technologies

The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.

Segmentation 5: by Application

Clinical Diagnostics
Translational Research
Other Applications

The Asia-Pacific NGS market (by technology type) is expected to be dominated by the translational research segment.

Segmentation 6: by End User

Academic and Research Institutes
Clinical Laboratories
Pharmaceutical and Biotechnology Companies
Other End Users

The Asia-Pacific NGS market (by end user) is expected to be dominated by the academic and research insitutes segment.

Segmentation 7: by Country

Asia-Pacific
- Japan
- India
- South Korea
- Australia
- Singapore
- New Zealand
- Rest-of-Asia-Pacific
Middle East
- U.A.E.
- K.S.A.
- Egypt
- Israel
- Rest-of-Middle East

The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E.

Recent Developments in the Asia-Pacific and Middle East NGS Market

In October 2022, PacBio introduced Revio and Onso, two new sequencing systems. Revio is a long-read sequencing system capable of sequencing up to 1,300 human whole genomes annually, while Onso is a benchtop short-read DNA sequencing platform. These systems enhance the scalability of PacBio's HiFi sequencing technology, supporting large-scale studies in human genetics, oncology, and agricultural genomics.
In September 2022, Illumina, Inc. launched Illumina Complete Long-Reads (INFINITY) for whole-genome sequencing (WGS). This innovation provided a high-performance, fully integrated sequencing method, compatible with all NovaSeq systems, enabling the synthesis of thousands of long-read genomes per year.
Also in September 2022, Illumina, Inc. unveiled the NovaSeq 6000 Dx, the first FDA-registered and CE-marked high-throughput in vitro diagnostic (IVD) sequencer. Designed for clinical applications, this platform ensures high compliance standards while delivering critical insights to improve patient care.
In August 2022, Illumina, Inc. partnered with the Minderoo Foundation, investing $27.8 million to advance genetic research on marine ecosystems. This collaboration utilized Illumina's NextSeq 2000 sequencing system to analyze marine biodiversity and better understand oceanic life.
In April 2022, Genomics England extended its partnership with a sequencing company to explore the therapeutic and scientific potential of comprehensive genomic analysis of cancer tumors using nanopore sequencing technology as part of an ongoing project.
In March 2022, a sequencing company launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, a fully automated system capable of generating sequencing data within a single day, streamlining diagnostic processes.
In January 2022, Pacific Biosciences of California, Inc. collaborated with Genomics England to further the 100,000 Genomes Project by leveraging long-read sequencing technology to detect genetic variants in cancer and rare disease cases. As part of this initiative, Genomics England re-sequenced biobank samples to identify additional genomic variations that short-read sequencing technologies might not effectively capture.

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific and Middle East NGS market:

Increasing Adoption of NGS in Various Research and Diagnostics Field
Growing Prevalence of Non-Communicable Diseases is Boosting the Demand for NGS
Advancement in the Performance of NGS Platforms

The market is expected to face some limitations as well due to the following challenges:

Dearth of Skilled Professionals in Middle East Countries
High Cost of Installation and Maintenance of the Equipment
Reimbursement and Regulatory Policies of NGS

How can this report add value to an organization?

Type: The Asia-Pacific and Middle East NGS market has been extensively segmented on the basis of various categories such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., over 70% of the total developments in the global Asia-Pacific and Middle East NGS market.

Competitive Strategy: The Asia-Pacific and Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the Asia-Pacific and Middle East NGS market analyzed and profiled in the study involve established and players that offer various kinds of NGS platforms, consumables, and services.

Executive Summary

Scope of the Study

Research Methodology

1. Asia-Pacific and Middle East NGS Market Overview

1.1 Market Outlook
- 1.1.1 Definitions
- 1.1.2 Inclusion and Exclusion Criteria
- 1.1.3 Market Size, 2024 - 2035, $Million
- 1.1.4 Key Findings
- 1.1.5 Market Growth Scenario
  - 1.1.5.1 Realistic Scenario
  - 1.1.5.2 Optimistic Scenario
  - 1.1.5.3 Pessimistic Scenario
1.2 Industry Outlook
- 1.2.1 NGS: Market Overview and Ecosystem
- 1.2.2 Asia-Pacific and Middle East NGS: Overview
- 1.2.3 Key Trends and Emerging Application of NGS in Asia-Pacific and Middle East
- 1.2.4 Patent Analysis
- 1.2.5 Pricing Analysis
  - 1.2.5.1 Instrument
  - 1.2.5.2 Consumables
- 1.2.6 Supply Chain Analysis
  - 1.2.6.1 Key Entities in Supply Chain
- 1.2.7 Regulatory Framework
  - 1.2.7.1 Asia-Pacific
  - 1.2.7.2 Middle East
- 1.2.8 Genome Projects
  - 1.2.8.1 Asia-Pacific
    - 1.2.8.1.1 China
    - 1.2.8.1.2 Japan
    - 1.2.8.1.3 India
    - 1.2.8.1.4 South Korea
    - 1.2.8.1.5 Singapore
    - 1.2.8.1.6 Other Asian Countries
  - 1.2.8.2 Middle East
    - 1.2.8.2.1 UAE
    - 1.2.8.2.2 Qatar
    - 1.2.8.2.3 Saudi Arabia
    - 1.2.8.2.4 Kuwait
    - 1.2.8.2.5 Other Middle East Countries
1.3 Market Dynamics
- 1.3.1 Market Drivers
  - 1.3.1.1 Impact Analysis
- 1.3.2 Market Restraints
  - 1.3.2.1 Impact Analysis
- 1.3.3 Market Opportunities

2. Asia-Pacific and Middle East NGS Market Analysis (By Offering), $Million, 2024-2035

2.1 Consumables
- 2.1.1 Library Preparation and Reagents
- 2.1.2 Sequencing Kits and Reagents
- 2.1.3 Others
2.2 Equipment
2.3 Services
- 2.3.1 Sequencing Services
- 2.3.2 Data Management Services

3. Asia-Pacific and Middle East NGS Market Analysis (By Workflow), $Million, 2024-2035

3.1 Sequencing
3.2 Pre-Sequencing
3.3 Data Analysis

4. Asia-Pacific and Middle East NGS Market Analysis (By Platform), $Million, 2024-2035

4.1 Overview
- 4.1.1 Asia-Pacific
- 4.1.2 Middle East
4.2 Illumina, Inc. (Asia-Pacific and Middle East)
- 4.2.1 iSeq
- 4.2.2 MiniSeq
- 4.2.3 MiSeq
- 4.2.4 NextSeq
- 4.2.5 NovaSeq
4.3 Thermo Fisher Scientific, Inc. (Asia-Pacific and Middle East)
- 4.3.1 Ion PGM
- 4.3.2 Ion Genestudio S5
- 4.3.3 Ion Proton
- 4.3.4 Ion Genexus
4.4 Pacific Biosciences of California, Inc. (Asia-Pacific and Middle East)
- 4.4.1 Sequel II/IIe
4.5 Oxford Nanopore Technologies plc. (Asia-Pacific and Middle East)
- 4.5.1 MinION
- 4.5.2 GridION
- 4.5.3 PromethION
4.6 Other Companies (Asia-Pacific and Middle East)

5. Asia-Pacific and Middle East NGS Market Analysis (By Throughput), $Million, 2024-2035

5.1 Overview
- 5.1.1 Asia-Pacific
- 5.1.2 Middle East
5.2 High-Throughput
5.3 Medium-Throughput
5.4 Low-Throughput

6. Asia-Pacific and Middle East NGS Market Analysis (By Technology Type), $Million, 2024-2035

6.1 Sequencing by Synthesis
6.2 Ion Torrent Semiconductor Sequencing
6.3 Single Molecule Real-time Sequencing
6.4 Nanopore Sequencing Technologies
6.5 Other Technologies

7. Asia-Pacific and Middle East NGS Market Analysis (By Application), $Million, 2024-2035

7.1 Clinical Diagnostics
- 7.1.1 Oncology
- 7.1.2 Infectious Diseases
- 7.1.3 Reproductive Genetics
- 7.1.4 Others
7.2 Translational Research
- 7.2.1 Clinical
- 7.2.2 Agricultural
- 7.2.3 Others

8. Asia-Pacific and Middle East NGS Market Analysis (By End User), $Million, 2024-2035

8.1 Pharmaceutical and Biotechnology Companies
8.2 Academic and Research Institution
8.3 Clinical Laboratories
8.4 Others

9. Asia-Pacific NGS Market Analysis (By Country), $Million, 2024-2035

9.1 Market Overview
9.2 Market Sizing and Forecast
- 9.2.1 Japan
- 9.2.2 China
- 9.2.3 India
- 9.2.4 South Korea
- 9.2.5 Australia
- 9.2.6 Singapore
- 9.2.7 New Zealand
- 9.2.8 Rest of Asia-Pacific

10. Middle East NGS Market Analysis (By Country), $ Million, 2024-2035

10.1 Market Overview
10.2 Market Sizing and Forecast
- 10.2.1 UAE
- 10.2.2 KSA
- 10.2.3 Israel
- 10.2.4 Egypt
- 10.2.5 Rest-of-Middle East

11. Asia-Pacific and Middle East NGS Market - Competitive Benchmarking and Company Profiles

11.1 Competitive Benchmarking
11.2 Competitive Landscape
- 11.2.1 Key Strategies and Developments by Company
  - 11.2.1.1 Funding Activities
  - 11.2.1.2 Mergers and Acquisitions
  - 11.2.1.3 Regulatory Approvals
  - 11.2.1.4 Partnerships, Collaborations, and Business Expansions
- 11.2.2 Market Share Analysis, 2024-2035
- 11.2.3 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by End User)
- 11.2.4 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by Throughput)
11.3 Company Profiles
- 11.3.1 BGI Group
- 11.3.2 Illumina, Inc.
- 11.3.3 Thermo Fisher Scientific, Inc.
- 11.3.4 Pacific Biosciences of California, Inc.
- 11.3.5 Oxford Nanopore Technologies plc
11.4 Emerging Companies (Asia-Pacific and Middle East)

한글목차

목차

개요

조사 범위

제1장 아시아태평양 및 중동의 NGS 시장 개요

제2장 아시아태평양 및 중동의 NGS 시장 분석(오퍼링별), 100만 달러, 2024-2035년

제3장 아시아태평양 및 중동의 NGS 시장 분석(워크플로우별), 100만 달러, 2024-2035년

제4장 아시아태평양 및 중동의 NGS 시장 분석(플랫폼별), 100만 달러, 2024-2035년

제5장 아시아태평양 및 중동의 NGS 시장 분석(Throughput별), 100만 달러, 2024-2035년

제6장 아시아태평양 및 중동의 NGS 시장 분석(기술 유형별), 100만 달러, 2024-2035년

제7장 아시아태평양 및 중동의 NGS 시장 분석(용도별), 100만 달러, 2024-2035년

제8장 아시아태평양 및 중동의 NGS 시장 분석(최종사용자별), 100만 달러, 2024-2035년

제9장 아시아태평양 NGS 시장 분석(국가별), 100만 달러, 2024-2035년

제10장 중동의 NGS 시장 분석(국가별), 100만 달러, 2024-2035년

제11장 아시아태평양 및 중동의 NGS 시장 - 경쟁 벤치마킹과 기업 개요